| Detected | Trial | Change |
|---|---|---|
| 2026-08-15 | NCT03630211 Autologous Stem Cell Transplantation in Patients With Systemic Sclerosis · Paul Szabolcs |
date change Primary completion pushed: 2026-08-01 -> 2028-08-01 |
| 2026-08-15 | NCT03630211 Autologous Stem Cell Transplantation in Patients With Systemic Sclerosis · Paul Szabolcs |
date change Completion pushed: 2026-08-01 -> 2028-08-01 |
| 2026-08-14 | NCT06646913 TENS in Scleroderma · University of Michigan |
Trial completed |
| 2026-08-14 | NCT06646913 TENS in Scleroderma · University of Michigan |
Phase changed: Phase 1 -> not applicable |
| 2026-08-14 | NCT06646913 TENS in Scleroderma · University of Michigan |
Primary endpoint(s) modified |
| 2026-08-14 | NCT06646913 TENS in Scleroderma · University of Michigan |
Enrollment reduced: 16 -> 11 participants |
| 2026-08-14 | NCT06646913 TENS in Scleroderma · University of Michigan |
date change Primary completion moved earlier: 2026-02 -> 2025-06-02 |
| 2026-08-14 | NCT06646913 TENS in Scleroderma · University of Michigan |
date change Completion moved earlier: 2026-05 -> 2025-06-30 |
| 2026-08-09 | NCT06614270 Anti-CD19 IL-10/IL15 CAR-NK Cells in Refractory/Relapsed Autoimmune Diseases · Second Affiliated Hospital, School of Medicine, Zhejiang University |
Sponsor changed: Second Affiliated Hospital, School of Medicine, Zhejiang University -> Second Affiliated Hospital, Zhejiang University, School of Medicine |
| 2026-08-09 | NCT06375005 Efficacy and Safety of Telitacicept in the Treatment of Systemic Sclerosis · Second Affiliated Hospital, School of Medicine, Zhejiang University |
Sponsor changed: Second Affiliated Hospital, School of Medicine, Zhejiang University -> Second Affiliated Hospital, Zhejiang University, School of Medicine |
| 2026-08-08 | NCT07734012 Mycophenolate After Stem Cell Transplant for Systemic Sclerosis · Ottawa Hospital Research Institute |
Primary endpoint(s) modified |
| 2026-08-06 | NCT07287670 EncompaSSc: Evaluation of MTX-474 in Participants With Diffuse Cutaneous Systemic… · Mediar Therapeutics |
Trial sites expanded: 6 -> 58 locations |
| 2026-08-04 | NCT07335562 A Study to Compare the Efficacy and Safety of BMS-986353 (Zolacabtagene- Autoleucel /… · Juno Therapeutics, Inc., a Bristol-Myers Squibb Company |
overall status: Recruiting → Not Yet Recruiting |
| 2026-08-04 | NCT05869955 A Study of CC-97540, CD-19-Targeted Nex-T CAR T Cells, in Participants With Severe… · Juno Therapeutics, Inc., a Bristol-Myers Squibb Company |
Enrollment closed, study ongoing |
| 2026-08-04 | NCT05869955 A Study of CC-97540, CD-19-Targeted Nex-T CAR T Cells, in Participants With Severe… · Juno Therapeutics, Inc., a Bristol-Myers Squibb Company |
Trial sites reduced: 54 -> 46 locations |
| 2026-08-01 | NCT07497087 A Study to Test Whether Nerandomilast Helps People With Systemic Sclerosis · Boehringer Ingelheim |
Recruitment opened |
| 2026-08-01 | NCT07497087 A Study to Test Whether Nerandomilast Helps People With Systemic Sclerosis · Boehringer Ingelheim |
Trial sites expanded: 236 -> 241 locations |
| 2026-07-31 | NCT06947460 CD19-BCMA CART Cell Therapy for Refractory SLE-LN, SSc, and pSS-PAH · Beijing GoBroad Hospital |
Primary endpoint(s) modified |
| 2026-07-31 | NCT06947460 CD19-BCMA CART Cell Therapy for Refractory SLE-LN, SSc, and pSS-PAH · Beijing GoBroad Hospital |
date change Primary completion pushed: 2026-07-01 -> 2026-07-31 |
| 2026-07-29 | NCT07295847 A Study of AZD0120 in Autoimmune Diseases · AstraZeneca |
Trial sites expanded: 18 -> 22 locations |
| First Posted | Trial | Sponsor | Phase |
|---|---|---|---|
| 2026-08-05 | NCT07748000 A Study of LIQ861 (Inhaled Treprostinil) in Adults With Systemic Sclerosis Who Have… | Liquidia Technologies, Inc. NEW | Phase 2 |
| 2026-08-04 | NCT07745725 A Phase II Study of TollB-001 Tablets in Systemic Sclerosis | Toll Biotech Co. Ltd. (Beijing) NEW | Phase 2 |
| 2026-07-29 | NCT07734012 Mycophenolate After Stem Cell Transplant for Systemic Sclerosis | Ottawa Hospital Research Institute NEW | Phase 2 |
| 2026-07-28 | NCT07729995 BAFF CAR-T Cells (LMY-922) for Treatment of Refractory Autoimmune Disease | Luminary Therapeutics NEW | Phase 1 |
| 2026-07-28 | NCT07732309 A Study of ATG-201 in Adult Participants With Autoimmune Diseases | Antengene Biologics Limited NEW | Phase 1 |
| 2026-07-21 | NCT07717060 Extracellular Vesicle Dynamics Predicting Vascular Complications and Treatment Response… | Fondazione Policlinico Universitario Agostino Gemelli IRCCS NEW | |
| 2026-06-30 | NCT07676266 A Study of C-CAR168 in the Treatment of Autoimmune Diseases Refractory to Standard Therapy | The Affiliated Hospital of Qingdao University NEW | Phase 1 |
| 2026-06-22 | NCT07661836 Personalized Online Occupational Therapy Intervention for Adults With Scleroderma | Universidad de Zaragoza NEW | |
| 2026-06-16 | NCT07649265 A Trial in Healthy Adult Participants and Adults With Autoimmune Disease to Test How… | Astex Pharmaceuticals NEW | Phase 1 |
| 2026-06-11 | NCT07642297 TL1A Inhibition in Systemic Sclerosis-Related Skin Fibrosis and Immunological… | Fondazione Policlinico Universitario Campus Bio-Medico NEW |
| NCT ID | Title | Sponsor | Status |
|---|---|---|---|
| Phase 4 | |||
| NCT06546540 | The Safety and Efficacy of Telitacicept in the Treatment of Systemic Sclerosis | Peking University Third Hospital | Recruiting |
| NCT07087912 | Safety and Immunogenicity of the Live Attenuated Tetravalent Butantan-Dengue Vaccine in… | University of Sao Paulo General Hospital | Recruiting |
| NCT06763783 | Vaccination Against Herpes Zoster in Patients With Inflammatory Rheumatic Diseases | Region Skane | Enrolling by Invitation |
| NCT05300932 | A Study Evaluating the Efficacy and Safety of Baricitinib in Systemic Sclerosis | Tongji Hospital | Active, Not Recruiting |
| NCT05879419 | Recombinant Herpes Zoster Vaccine in Patients With Autoimmune Rheumatic Diseases | University of Sao Paulo General Hospital | Active, Not Recruiting |
| Phase 3 | |||
| NCT06936215 | Safety and Efficacy of Baricitinib on Skin Tightening in Diffuse Cutaneous Systemic… | Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh | Recruiting |
| NCT07245238 | Topical Cannabidiol Lotion for Pruritus Relief in Scleroderma | Khon Kaen University | Recruiting |
| NCT06297096 | Study of the Efficacy of Nintedanib+Tocilizumab in Patients With Systemic Sclerosis and… | National Institute of Geriatrics, Rheumatology and Rehabilitation, Poland | Recruiting |
| NCT06549231 | Evaluation of Efficacy and Safety of Rituximab and Mycophenolate Mofetil Combination in… | University Hospital, Tours | Recruiting |
| NCT07497087 | A Study to Test Whether Nerandomilast Helps People With Systemic Sclerosis | Boehringer Ingelheim | Recruiting |
| NCT05198557 | A Study of MT-0551 in Patients With Systemic Sclerosis | Tanabe Pharma Corporation | Active, Not Recruiting |
| NCT05726630 | Clinical Study of Divozilimab in Patients With Systemic Scleroderma | Biocad | Active, Not Recruiting |
| NCT07691970 | Rollover Study for Participants Who Have Completed a Previous Clinical Study With… | AstraZeneca | Not Yet Recruiting |
| NCT05925803 | Determine Effectiveness of Anifrolumab In SYstemic Sclerosis (DAISY) | AstraZeneca | Active, Not Recruiting |
| NCT07335562 | A Study to Compare the Efficacy and Safety of BMS-986353 (Zolacabtagene- Autoleucel /… | Juno Therapeutics, Inc., a Bristol-Myers Squibb Company | Not Yet Recruiting |
| NCT07759557 | Efficacy of A Non-Invasive Botulinum Toxin Microneedle Pad for the Treatment of Secondary… | Khon Kaen University | Not Yet Recruiting |
| Phase 2/3 | |||
| NCT05878717 | A Study of the Efficacy and Safety of Belimumab in Adults With Systemic Sclerosis… | GlaxoSmithKline | Recruiting |
| NCT05098704 | Preventive Effect of Clopidogrel on the Systemic Sclerosis Development Risk | University Hospital, Bordeaux | Recruiting |
| Phase 2 | |||
| NCT05149768 | Open Label Extension Study of Brentuximab Vedotin in Early dcSSc | London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's | Recruiting |
| NCT06189495 | A Randomized, Double-blind, Placebo-controlled Phase II Clinical Study to Evaluate the… | Changchun GeneScience Pharmaceutical Co., Ltd. | Recruiting |
| NCT06375005 | Efficacy and Safety of Telitacicept in the Treatment of Systemic Sclerosis | Second Affiliated Hospital, School of Medicine, Zhejiang University | Recruiting |
| NCT06794008 | BCMA-CD19 CAR-T Therapy for Refractory Autoimmune Diseases | Peking University People's Hospital | Recruiting |
| NCT05785065 | Mycophenolate Mofetil in Systemic Sclerosis With Subclinical Interstitial Lung Disease | Centre hospitalier de l'Université de Montréal (CHUM) | Recruiting |
| NCT05029336 | Autologous Stem Cell Transplant (ASCT) for Autoimmune Diseases | Stephan Grupp MD PhD | Recruiting |
| NCT04797286 | Sildenafil for Early Pulmonary Vascular Disease in Scleroderma | Johns Hopkins University | Recruiting |